Pharmacologic Management of Urinary Incontinence, Voiding Dysfunction, and Overactive Bladder

Obstetrics and Gynecology Clinics of North America

Volumn 36, Issue 3, 2009, Pages 493-507

  Saks, Emily K ^a   Arya, Lily A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Female; Medication; Overactive bladder; Treatment; Urinary incontinence

Indexed keywords

ACETYLCHOLINE; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETHANECHOL; BOTULINUM TOXIN; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; DESMOPRESSIN; DOXAZOSIN; DULOXETINE; EPHEDRINE; ESTROGEN; FESOTERODINE; FLAVOXATE; GELNIQUE; IMIPRAMINE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROTOXIN; OXYBUTYNIN; PLACEBO; PROPIVERINE; PSEUDOEPHEDRINE; RESINIFERATOXIN; SANCTURA XR; SOLIFENACIN; TERAZOSIN; TOLTERODINE; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG;

APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; BEHAVIOR THERAPY; BLADDER SPHINCTER; BLURRED VISION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DETRUSOR MUSCLE; DRUG CHOICE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ELDERLY CARE; ERYTHEMA; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; MUSCLE CONTRACTILITY; NAUSEA; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RECEPTOR BLOCKING; REVIEW; SENSORY NERVE; SKIN IRRITATION; STRESS INCONTINENCE; URETHRA; URINE INCONTINENCE; XEROSTOMIA;

AGED; FEMALE; HUMANS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; URINATION DISORDERS;

EID: 70449732295     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2009.08.001     Document Type: Review

References (85)

1. de Groat W.C. A neurologic basis for the overactive bladder. Urology 50 Suppl 6A (1997) 36-52
2. DeLancey J.O. Structural support of the urethra as it relates to stress urinary incontinence: the hammock hypothesis. Am J Obstet Gynecol 170 6 (1994) 1713-1720
3. Fraser M.O., and Chancellor M.B. Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence. BJU Int 91 8 (2003) 743-748
4. Diokno A.C., and Taub M. Ephedrine in treatment of urinary incontinence. Urology 5 5 (1975) 624-625
5. Mariappan P., Ballantyne Z., N'Dow J.M., et al. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults. Cochrane Database Syst Rev 3 (2005) CD004742
6. Hunsballe J.M., and Djurhuus J.C. Clinical options for imipramine in the management of urinary incontinence. Urol Res 29 2 (2001) 118-125
7. Castleden C.M., Duffin H.M., and Gulati R.S. Double-blind study of imipramine and placebo for incontinence due to bladder instability. Age Ageing 15 5 (1986) 299-303
8. Woodman P.J., Misko C.A., and Fischer J.R. The use of short-form quality of life questionnaires to measure the impact of imipramine on women with urge incontinence. Int Urogynecol J Pelvic Floor Dysfunct 12 5 (2001) 312-315
9. Thor K.B., and Katofiasc M.A. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 274 2 (1995) 1014-1024
10. Bump R.C., Norton P.A., Zinner N.R., et al. Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response. Obstet Gynecol 102 1 (2003) 76-83
11. Steers W.D., Herschorn S., Kreder K.J., et al. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int 100 2 (2007) 337-345
12. Norton P.A., Zinner N.R., Yalcin I., et al. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 187 1 (2002) 40-48
13. Bump R.C., Voss S., Beardsworth A., et al. Long-term efficacy of duloxetine in women with stress urinary incontinence. BJU Int 102 2 (2008) 214-218
14. Nabi G., Cody J.D., Ellis G., et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 4 (2006) CD003781
15. Wein A.J., and Rovner E.S. Pharmacologic management of urinary incontinence in women. Urol Clin North Am 29 3 (2002) 537-550 viii
16. Abrams P., Andersson K.E., Buccafusco J.J., et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148 5 (2006) 565-578
17. Roxburgh C., Cook J., and Dublin N. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database Syst Rev 4 (2007) CD003190
18. Anderson R.U., Mobley D., Blank B., et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 161 6 (1999) 1809-1812
19. Andersson K.E., and Chapple C.R. Oxybutynin and the overactive bladder. World J Urol 19 5 (2001) 319-323
20. Hegde S.S. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 147 Suppl 2 (2006) S80-S87
21. Zobrist R.H., Quan D., Thomas H.M., et al. Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm Res 20 1 (2003) 103-109
22. Diokno A.C., Appell R.A., Sand P.K., et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 78 6 (2003) 687-695
23. Dmochowski R.R., Sand P.K., Zinner N.R., et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 62 2 (2003) 237-242
24. Staskin D.R., Dmochowski R.R., Sand P.K., et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol 181 4 (2009) 1764-1772
25. Diokno A., and Ingber M. Oxybutynin in detrusor overactivity. Urol Clin North Am 33 4 (2006) 439-445 vii
26. Van Kerrebroeck P., Kreder K., Jonas U., et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 57 3 (2001) 414-421
27. Cardozo L., Chapple C.R., Toozs-Hobson P., et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int 85 6 (2000) 659-664
28. Staskin D.R. Trospium chloride: distinct among other anticholinergic agents available for the treatment of overactive bladder. Urol Clin North Am 33 4 (2006) 465-473 viii
29. Rovner E.S. Trospium chloride in the management of overactive bladder. Drugs 64 21 (2004) 2433-2446
30. Cardozo L., Lisec M., Millard R., et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172 5 Pt 1 (2004) 1919-1924
31. Simpson D., and Wagstaff A.J. Solifenacin in overactive bladder syndrome. Drugs Aging 22 12 (2005) 1061-1069
32. Chapple C.R., Martinez-Garcia R., Selvaggi L., et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48 3 (2005) 464-470
33. Haab F., Stewart L., and Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 45 4 (2004) 420-429
34. Zinner N. Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder. Expert Opin Pharmacother 8 4 (2007) 511-523
35. Chapple C., Van K.P., Tubaro A., et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 52 4 (2007) 1204-1212
36. Nitti V.W., Dmochowski R., Sand P.K., et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 178 6 (2007) 2488-2494
37. Khullar V., Chapple C., Gabriel Z., et al. The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology 68 Suppl 2 (2006) 38-48
38. Gopal M., Haynes K., Bellamy S.L., et al. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol 112 6 (2008) 1311-1318
39. Shaya F.T., Blume S., Gu A., et al. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 11 Suppl 4 (2005) S121-S129
40. Yu Y.F., Nichol M.B., Yu A.P., et al. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 8 4 (2005) 495-505
41. Kelleher C.J., Cardozo L.D., Khullar V., et al. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104 9 (1997) 988-993
42. Hay-Smith J., Herbison P., Ellis G., et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 3 (2005) CD005429
43. Chapple C.R., Khullar V., Gabriel Z., et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54 3 (2008) 543-562
44. Sand P., Zinner N., Newman D., et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 99 4 (2007) 836-844
45. Malavaud B., Bagheri H., Senard J.M., et al. Visual hallucinations at the onset of tolterodine treatment in a patient with a high-level spinal cord injury. BJU Int 84 9 (1999) 1109
46. Kay G., Crook T., Rekeda L., et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 50 2 (2006) 317-326
47. Wagg A., Wyndaele J.J., and Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 4 1 (2006) 14-24
48. Schurch B., Stohrer M., Kramer G., et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164 3 Pt 1 (2000) 692-697
49. Cruz F., and Dinis P. Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms. Neurourol Urodyn 26 Suppl 6 (2007) 920-927
50. Karsenty G., Denys P., Amarenco G., et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 53 2 (2008) 275-287
51. Brubaker L., Richter H.E., Visco A., et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 180 1 (2008) 217-222
52. Duthie J., Wilson D.I., Herbison G.P., et al. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 3 (2007) CD005493
53. Apostolidis A., Dasgupta P., Denys P., et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol (2008) September 17, 2009. Epub ahead of print
54. Giannantoni A., Mearini E., Del Z.M., et al. Six-year follow-up of botulinum toxin a intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 55 3 (2009) 705-711
55. Chancellor M.B., and de Groat W.C. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 162 1 (1999) 3-11
56. Giannantoni A., Mearini E., Di Stasi S.M., et al. New therapeutic options for refractory neurogenic detrusor overactivity. Minerva Urol Nefrol 56 1 (2004) 79-87
57. Andersson K.E., Chapple C.R., Cardozo L., et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 19 4 (2009) 380-394
58. Hashim H., and Abrams P. Novel uses for antidiuresis. Int J Clin Pract Suppl 155 (2007) 32-36
59. Gopal M., Sammel M.D., Pien G., et al. Investigating the associations between nocturia and sleep disorders in perimenopausal women. J Urol 180 5 (2008) 2063-2067
60. Dykstra D.D., and Sidi A.A. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 71 1 (1990) 24-26
61. de Seze M., Petit H., Gallien P., et al. Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol 42 1 (2002) 56-62
62. Phelan M.W., Franks M., Somogyi G.T., et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 165 4 (2001) 1107-1110
63. Nitti V.W., Tu L.M., and Gitlin J. Diagnosing bladder outlet obstruction in women. J Urol 161 5 (1999) 1535-1540
64. Kumar A., Mandhani A., Gogoi S., et al. Management of functional bladder neck obstruction in women: use of alpha-blockers and pediatric resectoscope for bladder neck incision. J Urol 162 6 (1999) 2061-2065
65. Low B.Y., Liong M.L., Yuen K.H., et al. Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial. J Urol 179 4 (2008) 1461-1469
66. Taylor III J.A., and Kuchel G.A. Detrusor underactivity: clinical features and pathogenesis of an underdiagnosed geriatric condition. J Am Geriatr Soc 54 12 (2006) 1920-1932
67. Finkbeiner A.E. Is bethanechol chloride clinically effective in promoting bladder emptying? A literature review. J Urol 134 3 (1985) 443-449
68. Resnick N.M., and Yalla S.V. Detrusor hyperactivity with impaired contractile function: an unrecognized but common cause of incontinence in elderly patients. JAMA 257 22 (1987) 3076-3081
69. Kuo H.C. Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology 61 3 (2003) 550-554
70. Schaffer J., and Fantl J.A. Urogenital effects of the menopause. Baillieres Clin Obstet Gynaecol 10 3 (1996) 401-417
71. Cardozo L., Lose G., McClish D., et al. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand 83 10 (2004) 892-897
72. Cardozo L., Lose G., McClish D., et al. A systematic review of estrogens for recurrent urinary tract infections: third report of the Hormones and Urogenital Therapy (HUT) Committee. Int Urogynecol J Pelvic Floor Dysfunct 12 1 (2001) 15-20
73. Hendrix S.L., Cochrane B.B., Nygaard I.E., et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA 293 8 (2005) 935-948
74. Grady D., Brown J.S., Vittinghoff E., et al. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 97 1 (2001) 116-120
75. Alhasso A.A., McKinlay J., Patrick K., et al. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 4 (2006) CD003193
76. Burgio K.L., Kraus S.R., Menefee S., et al. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: a randomized trial. Ann Intern Med 149 3 (2008) 161-169
77. Drake M.J. Emerging drugs for treatment of overactive bladder and detrusor overactivity. Expert Opin Emerg Drugs 13 3 (2008) 431-446
78. Available at:. http://clinicaltrials.gov/ct2/show/NCT00343486?intr=%22GW427353%22&r ank=1 Accessed June 6, 2009
79. Available at:. http://clinicaltrials.gov/ct2/show/NCT00527033?cond=%22Urinary+Bladder%2 C+Overactive%22&rank=1 Accessed June 6, 2009
80. Safarinejad M.R., and Hosseini S.Y. Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double-blind, placebo-controlled, randomized study. Br J Clin Pharmacol 61 4 (2006) 456-463
81. Green S.A., Alon A., Ianus J., et al. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol 176 6 Pt 1 (2006) 2535-2540
82. Halaska M., Ralph G., Wiedemann A., et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 20 6 (2003) 392-399
83. Chapple C.R., Van Kerrebroeck P.E., Junemann K.P., et al. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int 102 9 (2008) 1128-1132
84. Wein A.J. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Expert Opin Investig Drugs 10 1 (2001) 65-83
85. Benson J.T., and Walters M.D. Neurophysiology and pharmacology of the lower urinary tract. In: Walters M.D., and Karram M.M. (Eds). Urogynecology and reconstructive surgery. 3rd edition (2007), Mosby and Elsevier, Philadelphia 33